
Global Chronic Urticaria Or Hives Drug Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Chronic Urticaria Or Hives Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Chronic Urticaria Or Hives Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Chronic Urticaria Or Hives Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Chronic Urticaria Or Hives Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Chronic Urticaria Or Hives Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Chronic Urticaria Or Hives Drug market include Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Panacea Biotec Limited, Mycenax Biotech Inc., Mabtech Limited, J Uriach Y Compania, S.A., GlaxoSmithKline Plc and Genentech, Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Chronic Urticaria Or Hives Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Chronic Urticaria Or Hives Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Chronic Urticaria Or Hives Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Chronic Urticaria Or Hives Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Chronic Urticaria Or Hives Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Chronic Urticaria Or Hives Drug sales, projected growth trends, production technology, application and end-user industry.
Chronic Urticaria Or Hives Drug Segment by Company
Novartis AG
Merck & Co., Inc.
AstraZeneca Plc
Panacea Biotec Limited
Mycenax Biotech Inc.
Mabtech Limited
J Uriach Y Compania, S.A.
GlaxoSmithKline Plc
Genentech, Inc.
Faes Farma, SA
ELORAC, Inc.
Biofrontera AG
Chronic Urticaria Or Hives Drug Segment by Type
BF-Derm-1
GDC-0853
GSK-2646264
Bilastine
Others
Chronic Urticaria Or Hives Drug Segment by Application
Clinic
Hospital
Others
Chronic Urticaria Or Hives Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Chronic Urticaria Or Hives Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Chronic Urticaria Or Hives Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Chronic Urticaria Or Hives Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Chronic Urticaria Or Hives Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Urticaria Or Hives Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chronic Urticaria Or Hives Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Urticaria Or Hives Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Chronic Urticaria Or Hives Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chronic Urticaria Or Hives Drug industry.
Chapter 3: Detailed analysis of Chronic Urticaria Or Hives Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Chronic Urticaria Or Hives Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Chronic Urticaria Or Hives Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Chronic Urticaria Or Hives Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Chronic Urticaria Or Hives Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Chronic Urticaria Or Hives Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Chronic Urticaria Or Hives Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Chronic Urticaria Or Hives Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Chronic Urticaria Or Hives Drug market include Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Panacea Biotec Limited, Mycenax Biotech Inc., Mabtech Limited, J Uriach Y Compania, S.A., GlaxoSmithKline Plc and Genentech, Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Chronic Urticaria Or Hives Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Chronic Urticaria Or Hives Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Chronic Urticaria Or Hives Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Chronic Urticaria Or Hives Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Chronic Urticaria Or Hives Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Chronic Urticaria Or Hives Drug sales, projected growth trends, production technology, application and end-user industry.
Chronic Urticaria Or Hives Drug Segment by Company
Novartis AG
Merck & Co., Inc.
AstraZeneca Plc
Panacea Biotec Limited
Mycenax Biotech Inc.
Mabtech Limited
J Uriach Y Compania, S.A.
GlaxoSmithKline Plc
Genentech, Inc.
Faes Farma, SA
ELORAC, Inc.
Biofrontera AG
Chronic Urticaria Or Hives Drug Segment by Type
BF-Derm-1
GDC-0853
GSK-2646264
Bilastine
Others
Chronic Urticaria Or Hives Drug Segment by Application
Clinic
Hospital
Others
Chronic Urticaria Or Hives Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Chronic Urticaria Or Hives Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Chronic Urticaria Or Hives Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Chronic Urticaria Or Hives Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Chronic Urticaria Or Hives Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Urticaria Or Hives Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chronic Urticaria Or Hives Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Urticaria Or Hives Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Chronic Urticaria Or Hives Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chronic Urticaria Or Hives Drug industry.
Chapter 3: Detailed analysis of Chronic Urticaria Or Hives Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Chronic Urticaria Or Hives Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Chronic Urticaria Or Hives Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
199 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Chronic Urticaria Or Hives Drug Sales Value (2020-2031)
- 1.2.2 Global Chronic Urticaria Or Hives Drug Sales Volume (2020-2031)
- 1.2.3 Global Chronic Urticaria Or Hives Drug Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Chronic Urticaria Or Hives Drug Market Dynamics
- 2.1 Chronic Urticaria Or Hives Drug Industry Trends
- 2.2 Chronic Urticaria Or Hives Drug Industry Drivers
- 2.3 Chronic Urticaria Or Hives Drug Industry Opportunities and Challenges
- 2.4 Chronic Urticaria Or Hives Drug Industry Restraints
- 3 Chronic Urticaria Or Hives Drug Market by Company
- 3.1 Global Chronic Urticaria Or Hives Drug Company Revenue Ranking in 2024
- 3.2 Global Chronic Urticaria Or Hives Drug Revenue by Company (2020-2025)
- 3.3 Global Chronic Urticaria Or Hives Drug Sales Volume by Company (2020-2025)
- 3.4 Global Chronic Urticaria Or Hives Drug Average Price by Company (2020-2025)
- 3.5 Global Chronic Urticaria Or Hives Drug Company Ranking (2023-2025)
- 3.6 Global Chronic Urticaria Or Hives Drug Company Manufacturing Base and Headquarters
- 3.7 Global Chronic Urticaria Or Hives Drug Company Product Type and Application
- 3.8 Global Chronic Urticaria Or Hives Drug Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Chronic Urticaria Or Hives Drug Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Chronic Urticaria Or Hives Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Chronic Urticaria Or Hives Drug Market by Type
- 4.1 Chronic Urticaria Or Hives Drug Type Introduction
- 4.1.1 BF-Derm-1
- 4.1.2 GDC-0853
- 4.1.3 GSK-2646264
- 4.1.4 Bilastine
- 4.1.5 Others
- 4.2 Global Chronic Urticaria Or Hives Drug Sales Volume by Type
- 4.2.1 Global Chronic Urticaria Or Hives Drug Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Chronic Urticaria Or Hives Drug Sales Volume by Type (2020-2031)
- 4.2.3 Global Chronic Urticaria Or Hives Drug Sales Volume Share by Type (2020-2031)
- 4.3 Global Chronic Urticaria Or Hives Drug Sales Value by Type
- 4.3.1 Global Chronic Urticaria Or Hives Drug Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Chronic Urticaria Or Hives Drug Sales Value by Type (2020-2031)
- 4.3.3 Global Chronic Urticaria Or Hives Drug Sales Value Share by Type (2020-2031)
- 5 Chronic Urticaria Or Hives Drug Market by Application
- 5.1 Chronic Urticaria Or Hives Drug Application Introduction
- 5.1.1 Clinic
- 5.1.2 Hospital
- 5.1.3 Others
- 5.2 Global Chronic Urticaria Or Hives Drug Sales Volume by Application
- 5.2.1 Global Chronic Urticaria Or Hives Drug Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Chronic Urticaria Or Hives Drug Sales Volume by Application (2020-2031)
- 5.2.3 Global Chronic Urticaria Or Hives Drug Sales Volume Share by Application (2020-2031)
- 5.3 Global Chronic Urticaria Or Hives Drug Sales Value by Application
- 5.3.1 Global Chronic Urticaria Or Hives Drug Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Chronic Urticaria Or Hives Drug Sales Value by Application (2020-2031)
- 5.3.3 Global Chronic Urticaria Or Hives Drug Sales Value Share by Application (2020-2031)
- 6 Chronic Urticaria Or Hives Drug Regional Sales and Value Analysis
- 6.1 Global Chronic Urticaria Or Hives Drug Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Chronic Urticaria Or Hives Drug Sales by Region (2020-2031)
- 6.2.1 Global Chronic Urticaria Or Hives Drug Sales by Region: 2020-2025
- 6.2.2 Global Chronic Urticaria Or Hives Drug Sales by Region (2026-2031)
- 6.3 Global Chronic Urticaria Or Hives Drug Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Chronic Urticaria Or Hives Drug Sales Value by Region (2020-2031)
- 6.4.1 Global Chronic Urticaria Or Hives Drug Sales Value by Region: 2020-2025
- 6.4.2 Global Chronic Urticaria Or Hives Drug Sales Value by Region (2026-2031)
- 6.5 Global Chronic Urticaria Or Hives Drug Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Chronic Urticaria Or Hives Drug Sales Value (2020-2031)
- 6.6.2 North America Chronic Urticaria Or Hives Drug Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Chronic Urticaria Or Hives Drug Sales Value (2020-2031)
- 6.7.2 Europe Chronic Urticaria Or Hives Drug Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Chronic Urticaria Or Hives Drug Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Chronic Urticaria Or Hives Drug Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Chronic Urticaria Or Hives Drug Sales Value (2020-2031)
- 6.9.2 South America Chronic Urticaria Or Hives Drug Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Chronic Urticaria Or Hives Drug Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Chronic Urticaria Or Hives Drug Sales Value Share by Country, 2024 VS 2031
- 7 Chronic Urticaria Or Hives Drug Country-level Sales and Value Analysis
- 7.1 Global Chronic Urticaria Or Hives Drug Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Chronic Urticaria Or Hives Drug Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Chronic Urticaria Or Hives Drug Sales by Country (2020-2031)
- 7.3.1 Global Chronic Urticaria Or Hives Drug Sales by Country (2020-2025)
- 7.3.2 Global Chronic Urticaria Or Hives Drug Sales by Country (2026-2031)
- 7.4 Global Chronic Urticaria Or Hives Drug Sales Value by Country (2020-2031)
- 7.4.1 Global Chronic Urticaria Or Hives Drug Sales Value by Country (2020-2025)
- 7.4.2 Global Chronic Urticaria Or Hives Drug Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.9.2 France Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.16.2 China Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.19.2 India Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Novartis AG
- 8.1.1 Novartis AG Comapny Information
- 8.1.2 Novartis AG Business Overview
- 8.1.3 Novartis AG Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Novartis AG Chronic Urticaria Or Hives Drug Product Portfolio
- 8.1.5 Novartis AG Recent Developments
- 8.2 Merck & Co., Inc.
- 8.2.1 Merck & Co., Inc. Comapny Information
- 8.2.2 Merck & Co., Inc. Business Overview
- 8.2.3 Merck & Co., Inc. Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Merck & Co., Inc. Chronic Urticaria Or Hives Drug Product Portfolio
- 8.2.5 Merck & Co., Inc. Recent Developments
- 8.3 AstraZeneca Plc
- 8.3.1 AstraZeneca Plc Comapny Information
- 8.3.2 AstraZeneca Plc Business Overview
- 8.3.3 AstraZeneca Plc Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.3.4 AstraZeneca Plc Chronic Urticaria Or Hives Drug Product Portfolio
- 8.3.5 AstraZeneca Plc Recent Developments
- 8.4 Panacea Biotec Limited
- 8.4.1 Panacea Biotec Limited Comapny Information
- 8.4.2 Panacea Biotec Limited Business Overview
- 8.4.3 Panacea Biotec Limited Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Panacea Biotec Limited Chronic Urticaria Or Hives Drug Product Portfolio
- 8.4.5 Panacea Biotec Limited Recent Developments
- 8.5 Mycenax Biotech Inc.
- 8.5.1 Mycenax Biotech Inc. Comapny Information
- 8.5.2 Mycenax Biotech Inc. Business Overview
- 8.5.3 Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Product Portfolio
- 8.5.5 Mycenax Biotech Inc. Recent Developments
- 8.6 Mabtech Limited
- 8.6.1 Mabtech Limited Comapny Information
- 8.6.2 Mabtech Limited Business Overview
- 8.6.3 Mabtech Limited Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Mabtech Limited Chronic Urticaria Or Hives Drug Product Portfolio
- 8.6.5 Mabtech Limited Recent Developments
- 8.7 J Uriach Y Compania, S.A.
- 8.7.1 J Uriach Y Compania, S.A. Comapny Information
- 8.7.2 J Uriach Y Compania, S.A. Business Overview
- 8.7.3 J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.7.4 J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Product Portfolio
- 8.7.5 J Uriach Y Compania, S.A. Recent Developments
- 8.8 GlaxoSmithKline Plc
- 8.8.1 GlaxoSmithKline Plc Comapny Information
- 8.8.2 GlaxoSmithKline Plc Business Overview
- 8.8.3 GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.8.4 GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Product Portfolio
- 8.8.5 GlaxoSmithKline Plc Recent Developments
- 8.9 Genentech, Inc.
- 8.9.1 Genentech, Inc. Comapny Information
- 8.9.2 Genentech, Inc. Business Overview
- 8.9.3 Genentech, Inc. Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Genentech, Inc. Chronic Urticaria Or Hives Drug Product Portfolio
- 8.9.5 Genentech, Inc. Recent Developments
- 8.10 Faes Farma, SA
- 8.10.1 Faes Farma, SA Comapny Information
- 8.10.2 Faes Farma, SA Business Overview
- 8.10.3 Faes Farma, SA Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Faes Farma, SA Chronic Urticaria Or Hives Drug Product Portfolio
- 8.10.5 Faes Farma, SA Recent Developments
- 8.11 ELORAC, Inc.
- 8.11.1 ELORAC, Inc. Comapny Information
- 8.11.2 ELORAC, Inc. Business Overview
- 8.11.3 ELORAC, Inc. Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.11.4 ELORAC, Inc. Chronic Urticaria Or Hives Drug Product Portfolio
- 8.11.5 ELORAC, Inc. Recent Developments
- 8.12 Biofrontera AG
- 8.12.1 Biofrontera AG Comapny Information
- 8.12.2 Biofrontera AG Business Overview
- 8.12.3 Biofrontera AG Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Biofrontera AG Chronic Urticaria Or Hives Drug Product Portfolio
- 8.12.5 Biofrontera AG Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Chronic Urticaria Or Hives Drug Value Chain Analysis
- 9.1.1 Chronic Urticaria Or Hives Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Chronic Urticaria Or Hives Drug Sales Mode & Process
- 9.2 Chronic Urticaria Or Hives Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Chronic Urticaria Or Hives Drug Distributors
- 9.2.3 Chronic Urticaria Or Hives Drug Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.